What is Derma Sensor?
DermaSensor Inc. operates at the intersection of artificial intelligence and clinical dermatology. The company specializes in the design and manufacture of handheld, non-invasive devices that utilize advanced spectroscopy and machine learning algorithms to evaluate skin lesions for malignancy in seconds. By equipping primary care providers with these tools, DermaSensor addresses a significant public health challenge: the lack of routine skin cancer screenings for the general population. The company's current market position is bolstered by its CE Mark and active commercial availability in select international regions, reflecting a robust regulatory and operational foundation.
How much funding has Derma Sensor raised?
Derma Sensor has raised a total of $21.8M across 4 funding rounds:
Debt
$150K
Series A
$11.5M
Debt
$162K
Other Financing Round
$10M
Debt (2020): $150K with participation from PPP
Series A (2020): $11.5M led by SternAegis Ventures, David Matlin, Chris Dewey, and Dr. Maurice R. Ferre
Debt (2021): $162K supported by PPP
Other Financing Round (2022): $10M featuring Ceros Capital Markets
Key Investors in Derma Sensor
Ceros Capital Markets
A global investment platform specializing in fundraising for MedTech and Biotech companies, with a focus on disruptive technologies in medical devices and digital health.
SternAegis Ventures
A firm providing principal investing, investment banking, and strategic consulting services to accelerate growth for qualified small businesses.
David Matlin
An individual investor participating in the strategic growth of the company.
What's next for Derma Sensor?
With the recent influx of capital, DermaSensor is well-positioned to accelerate its global commercialization strategy and navigate the regulatory pathways required for entry into broader international markets. The focus remains on enhancing the clinical utility of their diagnostic platform while maintaining cost-effectiveness for healthcare providers. As the company scales, the strategic deployment of these funds will likely prioritize clinical validation studies and the expansion of their sales infrastructure, ensuring that their technology becomes a standard component of the primary care toolkit. The firm's ability to integrate seamlessly into existing clinical workflows will be the primary driver of its long-term value proposition in the competitive landscape of digital health and medical diagnostics.
See full Derma Sensor company page
